The management of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving due to continual updates from ongoing clinical trials on recently approved and emerging treatment approaches. Clinicians therefore need to stay abreast with recent progress to enable improved outcomes for patients. 

This educational Clinical Clip will highlight important advances in RRMM based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting

The introduction of chimeric antigen receptor (CAR) T-cell therapies has shifted the paradigm for several incurable and refractory hematologic malignancies and currently various cellular immunotherapies are under investigation. To ensure updated ongoing care for patients, clinicians need to be familiar with recent clinical trial evidence on approved and emerging CAR T-cell therapies. 

This educational Clinical Clip focused on CAR T-cell approaches has summarized key data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Clinicians need to keep up with recent progress in low-risk myelodysplastic syndromes (MDS) to facilitate appropriate integration of newly approved and novel therapies. 

This educational Clinical Clip will highlight key updates in low-risk MDS based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Until recently, there has been a lack of treatment options for high-risk MDS. An increased understanding of the genetics and signaling pathways has led to the development of several novel agents and combinations for the treatment of high-risk MDS.

High-risk myelodysplastic syndromes (MDS) pose a challenge in terms of diagnosis, risk stratification, and treatment. Additionally, in recent years, the clinical, molecular, cellular, and immunological factors associated with high-risk MDS have become clearer.

These certified AMA/ANCC/ACPE activities feature a discussion among three experts that will review the current and emerging treatment landscape of high-risk myelodysplastic syndromes (MDS). The program includes two activities that will feature the faculty discussing recent updates in the standard of care for high-risk MDS and what is on the horizon for high-risk MDS.

This certified CME/CNE activity features a recorded discussion among three experts that reviews the latest research and options for the management of patients with MPNs.

This certified CME/CNE activity features a recorded discussion among three lung cancer experts that reviews the latest options for the management of early stage lung cancer.

These certified CME/CNE interactive case presentations will review the latest management strategies and treatment options for the management of acute leukemia.